Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Inclusion Criteria: * Weigh between 35-135 kilograms * Low or int-1 risk MDS * Ferritin \>1000 micrograms/liter at screening * History of transfusion of 15 to 75 Packed Red Blood Cells (PRBC) units * Anticipated to be transfused with at least 8 units of PRBCs annually during the study * Women of child-bearing potential using effective methods of contraception during dosing of study treatment Exclusion Criteria: * More than 6 months of cumulative ICT (such as daily deferasirox (Exjade®) or deferiprone or 5×/week deferoxamine) * More than 3 years since patient began receiving regular transfusions (2 units per 8 weeks or 4 units received in a 3 month period) * Significant proteinuria * History of hospitalization for congestive heart failure; other heart conditions as specified in the protocol * Systemic diseases which would prevent study treatment * Hepatitis B; Hepatitis C; HIV * Liver cirrhosis * Pregnant, or breast-feeding patients, or patients of child-bearing potential not employing an effective method of birth control * History of drug or alcohol abuse within the 12 months prior to enrollment